This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech , today announced European CE mark approval of the VARIPULSE Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrialfibrillation ( AF ) using pulsed field ablation (PFA). AtrialFibrillation.
“Therefore, we have made the decision to offer only DX technology for new patients needing a single-chamber ICD, providing equivalent therapies along with additional atrial monitoring data, as recommended by current guidelines.” For more information: [link] References: Thomas G, Choi DY, Doppalapudi H, et al. Technol Health Care.
Case submitted and written by Mazen El-Baba MD, with edits from Jesse McLaren and edits/comments by Smith and Grauer A 90-year old with a past medical history of atrialfibrillation, type-2 diabetes, hypertension, dyslipidemia, presented with acute onset chest/epigastric pain, nausea, and vomiting.
The American College of Cardiology (ACC) and the American Heart Association (AHA) recently published new guidelines for the diagnosis and management of patients with atrialfibrillation (AF). link] ACC/AHA Release Updated AtrialFibrillation Guidelines for 2023. Sources: Joglar, J, Chung, M. J Am Coll Cardiol.
myocardial infarction), arrhythmias, valvular pathology, shunts, or outflow obstructions. Smith comment: In a large randomized trial of dopamine vs. norepinephrine (11) for shock which was published after the above-mentioned recommendations, dopamine had more adverse events (especially severe dysrhythmias, and especially atrialfibrillation).
Atrialfibrillation is the most common heart rhythm disorder in adults, affecting more than 5 million people in the U.S., The 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of AtrialFibrillation noted that abstaining from caffeine to prevent heart rhythm disturbances is of no benefit to people with AFib.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content